Ask AI
ProCE Banner Activity

TROP-2 and TNBC: Personalizing Patient Care Using Current Evidence and Innovative ADC-Based Therapeutic Strategies

Slideset

This activity reviews current and emerging clinical evidence for TROP-2–directed antibody–drug conjugates in unresectable locally advanced and metastatic triple-negative breast cancer, including efficacy and safety data from key clinical trials evaluating sacituzumab govitecan and datopotamab deruxtecan. It addresses treatment selection and sequencing based on PD-L1 status, prior therapy, disease characteristics, and patient-specific factors, as well as strategies to recognize and manage treatment-related adverse events. The content is designed to support evidence-based, individualized treatment decisions and proactive toxicity management as TROP-2–directed therapies become increasingly integrated into TNBC care.

Released: August 10, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

Oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other community HCPs caring for patients with triple-negative breast cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate current and emerging treatment clinical data evaluating TROP2 ADC-based combinations for all patients across first-line mTNBC

  • Synthesize a comprehensive treatment plan employing agents that target TROP2 in patients with mTNBC who experience disease progression on frontline therapy aligned with current treatment guidelines and expert recommendations

  • Design a tailored supportive care plan to manage treatment-related AEs in patients receiving TROP2-directed therapy, emphasizing QoL and patient comfort

  • Implement strategies supporting equitable access to novel TROP2 ADCs and clinical trials in patients with TNBC who are at risk for poor outcomes based on race, ethnicity, gender identity, and/or socioeconomic status